2016-11-01



Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

Get this in your inbox everyday by subscribing to our newsletters.

5. Fresenius acquires Xenios



Fresenius said yesterday it acquired lung & cardiac focused medtech company Xenios from German venture capital group zfhn Zukunftsfonds Heilbronn for an undisclosed amount.

Xenios was formed in 2013 after zfhn combined earlier acquisitions Novalung and Medos Medizintechnik under the Xenios moniker. The company develops and produces systems for minimally invasive lung and cardiac assistance, and employs more than 260 employees. Read more

4. Edwards Lifesciences subsidiary CardiAQ Valve wins another $21m in Neovasc patent spat



A federal judge in Massachusetts yesterday added $21 million to the $70 million Neovasc owes Edwards Lifesciences subsidiary CardiAQ Valve in their spat over replacement heart valve technology.

A jury in May awarded $70 million to CardiAQ after finding that Neovasc misappropriated trade secrets in developing its Tiara transcatheter mitral valve replacement device. Edwards inherited the lawsuit when it acquired CardiAQ Valve for $400 million in August 2014. Read more

3. TCT 2016: TAVR to the fore on Day 2

The annual Transcatheter Cardiovascular Therapeutics conference is under way in Washington, D.C., with late-breaking study results beginning Oct. 29. We’ll update this post throughout the day as new results come in, so be sure to check back for the latest news out of TCT 2016.

After stents took center stage Day 1, with a raft of studies covering the latest on the bioresorbable front, transcatheter valve replacements were the focus on Day 2 at the Transcatheter Cardiovascular Therapies conference. Read more

2. University of California sues Boston Scientific, St. Jude Medical over afib ablation patents

The University of California last week sued St. Jude Medical and Boston Scientific, alleging that the medical device companies infringe its patents covering a standard treatment for atrial fibrillation.

The lawsuits, filed in the U.S. District Court for Northern California, allege that Boston Scientific and St. Jude infringe a pair of patents covering the invention by UC-San Francisco professor Dr. Michael Lesh of a technique to isolate the pulmonary vein via catheter ablation. Read more

1. Report: Boston Scientific pauses Lotus Edge heart valve in Europe

Boston Scientific is reportedly pausing implantations of its next-generation Lotus Edge replacement heart valve in Europe to investigate a locking mechanism issue.

Marlborough, Mass.-based Boston Scientific has implanted about 200 of the Lotus Edge transcatheter aortic valve replacements in Europe, according to Barclays analyst Matthew Taylor, encountering about a 4% rate of “some issues with [the] locking mechanism of the valve.” Read more

The post MassDevice.com +5 | The top 5 medtech stories for November 1, 2016 appeared first on MassDevice.

Show more